Ultra-Long-Acting MPT In-Situ Forming Implant
ISFI
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Subdermal
-
Intended Duration:
- Not Yet Determined
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): University of North Carolina
Details
- API: Dolutegravir, Cabotegravir, Etonogestrel, Medroxyprogesterone Acetate
- Target: Progesterone Receptor
-
Mechanism of Action:
- Endometrial Changes
- Cervical Mucus Changes
- Ovulation Inhibition
- Anti-Microbial
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Potential MPT
- Promising Attributes: The method offers both pregnancy prevention and HIV prevention. A long-acting MPT could potentially increase compliance to STI and unplanned pregnancy prophylactic regimens.
Product Status
Active Pre-Clinical Research
History
2021: NIH grant awarded to explore ultra-long- acting "injectable implant" formulations providing steady release over several months of antiretroviral drugs in combination with a contraceptive drug.
2024: Research published demonstrating the ability to co-formulate antiretrovirals (dolutegravir or cabotegravir) with contraceptives etonogestrel or medroxyprogesterone acetate in an in-situ forming implant. Implant is well-tolerated with sustained plasma concentrations up to 90 days. API combination is not finalized - current test products indicate a number of potentially viable combinations, including LNG for contraception.